<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01862978</url>
  </required_header>
  <id_info>
    <org_study_id>MTSVKNEUROL001</org_study_id>
    <nct_id>NCT01862978</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke</brief_title>
  <acronym>Heparinas</acronym>
  <official_title>Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Martin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Martin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to show the efficacy and safety of heparin and nadroparin in the
      acute phase of ischemic stroke. Therapeutic agents are administered at intervals of 4.5 to 2
      hours after onset of clinical signs. Overall administration of anticoagulant agents will test
      72 hours.

      Randomized patients will be divided into three groups. The first group of patients will
      receive heparin intravenously at the beginning of 2500 UI bolus intravenously, followed by
      intravenous pump 1000 UI / h (18-20 IU / kg / hr) to reach 2-2.5 times the baseline aPTT.
      After 24 hours, patients will receive the group Nadroparin subcutaneously in the therapeutic
      dose.

      Second group of patients will be administered subcutaneously Nadroparin the therapeutic dose
      as recommended.

      The third group of patients are those who will receive placebo intravenously and 24 hours
      after receiving nadroparin subcutaneously in the therapeutic dose.

      All patients will receive after 24 hours of starting treatment 100 mg of aspirin per orally.

      For initiation of treatment will be assessed:

        -  Modified Rankin Scale, National Institutes of Health Stroke Scale, inclusion, exclusion
           criteria

        -  Sign the informed consent and patient randomization

        -  Laboratory parameters: glucose, creatinine, GGT, K, Na, Cl, blood count, basic
           coagulation

        -  Women of childbearing age (pregnancy test)

        -  History, clinical presentation, medical history, basic internal review of the status
           (blood pressure, pulse, body temperature, etc.).

        -  Initial CT examination of the brain

        -  EKG

        -  USG sections of extracranial carotid and vertebral arteries

        -  special hematology factors

      If a patient meets all the necessary criteria, he may be given the test substance. During the
      first 24 hours will be monitored at regular intervals vital functions.

      After 24 hours, each patient received subcutaneous Nadroparin the therapeutic dose and also
      100 mg of aspirin per orally.

      In the interval from 24 to 30 hours of starting treatment the patient will be made:

        -  Control CT brain

        -  EKG

        -  Basic coagulation

        -  Reduction to stop treatment for newly identified haemorrhage or severe and extensive
           focal cerebral ischemia by CT scan

        -  special hematology factors

           72 hours, 7, 30 and 90 days after starting treatment, the patient's clinical evaluation
           using the Modified Rankin Scale, National Institutes of Health Stroke Scale and Barthel
           Index.

      Safety endpoints: mortality, adverse side effects, bleeding
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of nadroparine or heparin</measure>
    <time_frame>DAY 3,7,30,90</time_frame>
    <description>Safety - incidence of intracranial hemorhage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of nadroparine or heparin</measure>
    <time_frame>DAY 3,7, 30, 90</time_frame>
    <description>Efficacy -level of improvement measured by mRS, and NIHSS</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receiving Heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nadroparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receiving nadroparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin</intervention_name>
    <arm_group_label>Nadroparin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_label>Nadroparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ischemic stroke

          -  female or male gender

          -  mRS (modified Rankin Scale) 0-1 (min one month before the event)

          -  NIHSS ≥ 6 and ≤ 25

          -  Age: 18-80 years

          -  initiation of therapy in the interval from 4.5 to 24 hours from onset of symptoms of
             ischemic stroke

          -  focal neurological deficit of at least 30 min, which was significantly obviously does
             not disappear before treatment

          -  patient will participate voluntarily and signed informed consent. Informed consent
             will be obtained from each patient, guardian or close relative

          -  patients who are unable to sign, but who are able to understand what means to
             participate in the study, may give informed consent through eyewitness

          -  willingness and ability to comply with the protocol

        Exclusion Criteria:

          -  intracranial hemorrhage confirmed by CT scan

          -  CT image heavy and extensive focal cerebral ischemia

          -  lacunar syndrome

          -  epileptic seizure at the beginning of ischemic stroke

          -  previous or planned treatment with intravenous, intra-arterial thrombolysis,
             mechanical recanalization or ultrasound assisted thrombolysis

          -  stroke, myocardial infarction, head trauma in the last 3 months

          -  tromboctov count below 100 000/mm ³

          -  therapeutically uncontrolled blood pressure: systolic blood pressure&gt; 185 mmHg or
             diastolic blood pressure&gt; 110 mmHg

          -  therapeutically uncontrolled blood glucose ˂ 2.77 or&gt; 22.15 mmol / l

          -  Known bleeding diathesis, other coagulopathies, severe hepatopathy, severe nephropathy

          -  patients receiving oral anticoagulants

          -  current or previous life-threatening bleeding

          -  major surgery less than 2 weeks ago

          -  known malignancy

          -  active TB

          -  pregnancy

          -  allergy to Heparin or Fraxiparine

          -  known alcohol abuse and / or drugs

          -  active participation in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Nosal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jessenius Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Egon Kurca, MD, PhD, prof</last_name>
    <role>Study Director</role>
    <affiliation>Jessenius Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladimir Nosal, MD, PhD</last_name>
    <phone>+421905764991</phone>
    <email>vnosal@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jana Dluha, MD</last_name>
    <phone>+421905514377</phone>
    <email>jana.dluha@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neurology Clinic Univeristy Hospital in Martin</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Dluha, MD</last_name>
      <phone>+421905514377</phone>
      <email>jana.dluha@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vladimir Nosal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Egon Kurca, MD,PhD,prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jana Dluha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Sivak, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jozef Michalik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ema Kantorova, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milan Grofik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milan Kratky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Kubisz, MD,DSc,prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Chudy, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Duraj, Mgr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jela Ivankova, RNDr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2013</study_first_posted>
  <last_update_submitted>August 14, 2013</last_update_submitted>
  <last_update_submitted_qc>August 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Martin</investigator_affiliation>
    <investigator_full_name>Vladimir Nosal, MD, PhD</investigator_full_name>
    <investigator_title>Prof.assistant</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Heparin</keyword>
  <keyword>Nadroparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Nadroparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

